The U.S. Food and Drug Administration accepted Acadia Pharmaceuticals Inc.’s application for an antipsychotic drug to treat dementia patients with hallucinations and delusions.
Early data released from trials of three potential coronavirus vaccines, including a closely watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight Covid-19 without serious side effects.
Synairgen shares exploded after the announcement of positive results from a clinical trial of the UK-based biotech company’s wholly owned inhaled formulation of interferon beta in Covid-19 patients.
German biotech firm BioNTech and U.S. drugmaker Pfizer reported additional data showing their experimental Covid-19 vaccine was safe and induced an immune response in patients.
An experimental coronavirus vaccine being developed by AstraZeneca and the University of Oxford was safe and produced an immune response in early-stage clinical trials, data showed, keeping alive the hope AZD1222 could be in use by the end of 2020.
A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.
Eli Lilly’s experimental treatment mirikizumab for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a Phase III comparison study.
The anti-malaria drug touted by U.S. President Donald Trump as a Covid-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
Phase I data from the Covid-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of a potential COVID-19 vaccine in advance of the company producing any of the medicines, the company’s Chief Financial Officer Joseph Wolk told Reuters in an interview.
